A Phase II Evaluation of Gefitinib in the Treatment of Persistent or Recurrent Endometrial Cancer: A Gynecologic Oncology Group Study

BACKGROUND: A phase II trial was performed to evaluate the efficacy and safety of gefitinib in patients with persistent/recurrent endometrial cancer. METHODS: Women with histologically confirmed persistent/recurrent endometrial cancer were treated with 500 mg oral gefitinib daily until progression o...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Leslie, Kimberly K., Sill, Michael W., Fischer, Edgar, Darcy, Kathleen M., Mannel, Robert S., Tewari, Krishnansu S., Hanjani, Parviz, Wilken, Jason A., Baron, Andre T., Godwin, Andrew K., Schilder, Russell J., Singh, Meenakshi, Maihle, Nita J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3700732/
https://ncbi.nlm.nih.gov/pubmed/23438670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2013.02.019
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi